Exclusive-UnitedHealth eyes $1 billion deal to exit Latin America as insurer refocuses on US, sources say

UnitedHealth Group is reportedly considering bids of approximately $1 billion for its Banmedica subsidiary, which operates in Colombia and Chile, as the company seeks to refocus on its U.S. operations amid recent challenges, including an earnings miss, a reported criminal probe into alleged Medicare fraud, and leadership changes. The move to exit Latin America, after previously divesting from Brazil and Peru, comes after failed expansion plans dating back to 2018. Bids have been submitted by firms including Acon Investments, Patria Investments, Christus Health, and Auna, with a deadline for binding proposals expected in July.

Analysis

UnitedHealth Group is actively seeking to divest its Latin American operations, Banmedica, which operates in Colombia and Chile, for approximately $1 billion, signaling a strategic retreat to concentrate on its core U.S. market. This move gains urgency amidst a confluence of severe challenges for the insurer, including a significant earnings miss, the ouster of CEO Andrew Witty who was replaced by Steve Hemsley, a reported criminal investigation into alleged Medicare fraud—which UnitedHealth states it has not been notified about by the Department of Justice, affirming the integrity of its operations—and the recent murder of UnitedHealthcare CEO Brian Thompson. The company's shares have suffered a substantial decline, falling 25.5% in May and 40% year-to-date, reflecting deep investor concern. The targeted $1 billion sale price for Banmedica, which generates over $200 million in annual EBITDA, implies a valuation multiple of less than 5x EBITDA, a stark contrast to the approximately 12x EBITDA UnitedHealth paid for the subsidiary in 2018, underscoring the financial underperformance or distressed nature of this international divestiture. This sale follows exits from Brazil in 2023 and Peru in March, marking a definitive end to the South American growth strategy initiated in 2018. Four non-binding bids from entities including Acon Investments, Patria Investments, Christus Health, and Auna are currently under consideration, with binding proposals anticipated by July.

Key Decisions for Investors

• Investors should closely monitor the progress of the Banmedica divestiture, developments concerning the reported criminal probe, and management's ability to stabilize operations, as these are critical to UnitedHealth's near-term performance and stock recovery.
• Given UnitedHealth's significant 40% year-to-date share price decline and its strategic refocus on the U.S., investors must assess whether current valuations adequately reflect the severe operational, legal, and governance risks, or if a turnaround under new leadership presents a viable opportunity.
• The potential sale of Banmedica at a sub-5x EBITDA multiple, substantially below its acquisition multiple, warrants careful consideration by bidders regarding the asset's true value and highlights for all investors the significant risks and capital destruction from UnitedHealth's failed Latin American expansion.